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OBJECTIVES We sought to gain insights into the early recurrence of atrial fibrillation (ERAF) after
cardioversion shocks delivered by permanently implanted rhythm management systems.
BACKGROUND Several reports have characterized ERAF, but these reports used a limited definition and did
not evaluate an association between clinical or device variables and ERAF.
METHODS A total of 144 patients with recurrent, drug-resistant, symptomatic atrial fibrillation (AF)
underwent implantation of an atrial rhythm management system (Medtronic Jewel AF,
Model 7250, Minneapolis, Minnesota). The device was programmed to deliver cardioversion
shocks automatically and/or on patient command. The incidence of ERAF was evaluated
after 1,092 successful shocks among 97 patients. Three different ERAF definitions were used:
recurrence within 1 min, 1 h or 1 day. Multiple clinical and device variables were assessed for
their relationship with ERAF.
RESULTS The per-patient incidences of ERAF were 44%, 61% and 70% for ERAF within 1 min, 1 h
and 1 day, respectively. The per-episode incidences of ERAF were 17%, 30% and 43% for
ERAF within 1 min, 1 h and 1 day, respectively. Variables that were independently associated
with ERAF included AF duration 3 h before termination, more than one shock required
to cardiovert and the absence of a previous myocardial infarction. The most potent variable
was AF duration 3 h, associated with a threefold increase in the incidence of ERAF.
CONCLUSIONS Recurrence of AF early after ambulatory shock cardioversion is common. In this retrospective
study, both clinical and device variables were predictive. (J Am Coll Cardiol 2002;40:93–9)
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Early recurrence of atrial fibrillation (ERAF) has been
observed after successful atrial cardioversion mediated by
direct-current shock, most recently those delivered via
permanently implanted systems (1–9). Early recurrence of
atrial fibrillation represents a serious obstacle in the path to
broadened use of “device-based” strategies for atrial rhythm
control. Although previous reports have chronicled the
incidence of ERAF, the definitions used were limited to
those episodes occurring within minutes of a successful
shock. From the patient’s perspective, such a definition may
be inadequate, as atrial fibrillation (AF) recurrence within
hours or days of a successful shock, if occurring regularly,
would not be tolerable. In addition, no report has addressed
the predictors of ERAF. The characterization of risk factors
may permit the immediate refinement of patient manage-
ment and provide insights for the future development of
improved therapeutic strategies.
In the present study, we investigated the incidence of
post-shock ERAF in a cohort of patients who underwent
implantation of an atrial rhythm management system. We
extend previous reports by characterizing ERAF using
intervals ranging from 1 min to 1 day, assessing individual
incidences and evaluating multiple variables for significant
association.
METHODS
Patients. The data were compiled from 146 consecutive
patients from multiple centers who were enrolled in a study
evaluating the Jewel AF device (model 7250, Medtronic,
Inc.; Minneapolis, Minnesota) and lead system. Participat-
ing centers and investigators have been acknowledged pre-
viously (10). Each patient fulfilled the following enrollment
criteria: 1) 2 symptomatic atrial tachyarrhythmia events
within three months of system implantation, with electro-
cardiographic documentation of at least one episode; 2)
inefficacy and/or intolerance of at least one type I or III
anti-arrhythmic drug; and 3) no history of clinically impor-
tant ventricular arrhythmia. Exclusion criteria included New
York Heart Association functional class IV heart failure,
cardiac surgery within the previous month, a left atrial
thrombus documented within the previous 6 months, a
cerebrovascular accident within the previous 12 months, a
mechanical tricuspid valve and life expectancy 1 year.
Each patient gave written, informed consent, according to a
protocol approved by the Human Subjects Committee of
the institution at which the devices were implanted. Patient
characteristics are summarized in Table 1.
Device. The Jewel AF system is an implantable dual-
chamber cardioverter-defibrillator system capable of sens-
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ing, pacing and defibrillation in both the atrium and
ventricle. Atrial tachyarrhythmia detection is programmable
in two zones—atrial tachycardia and AF—distinguished by
the rate and regularity on the atrial electrogram. For the
purposes of the present study, all atrial tachyarrhythmias
have been termed AF. The positive predictive accuracy for
spontaneous atrial tachyarrhythmia detection by the 7250
device was previously shown to be 99% (10). Undersensing
was minimized by an auto-adjusting sensitivity and a 30-ms
cross-chamber blanking period.
Therapies for AF included antitachycardia or 50-Hz
burst pacing and shocks. Atrial arrhythmia prevention
features included a switchback delay (high-rate DDI pacing
continued for a programmable duration immediately after
an atrial tachyarrhythmic event) and atrial rate stabilization
(which prevents long pauses after premature atrial complex-
es). Specific device programming for individual patients was
at the discretion of the investigator (Table 2).
In the present study, a coil-bearing lead located in the
coronary sinus comprised a portion of this circuit in 85
patients. Among the patients without a coronary sinus lead,
the most common circuit incorporated two coils (right
ventricle and superior vena cava) on a single lead and the
device can (n  47). Shocks could be delivered automati-
cally or on patient command. The timing of commanded
shocks relative to AF onset was not controlled. Automatic
shocks were programmed to occur after a sustained AF
duration (range 1 min to 24 h) and, in some cases, only at
selected nighttime hours.
After each shock, the atrial interelectrogram interval was
monitored. As defined by the device, a shock was successful
in terminating an AF event if five consecutive ventricular
beats occurred during sinus or atrial paced rhythm. The
ERAF was defined as a newly detected AF event occurring
after a successful shock. In the present study, ERAF was
defined by using three nonexclusive terms: 1) ERAF1 min 
successful shock followed by AF within 1 min; 2)
ERAF1 h  successful shock followed by AF within 1 h;
Abbreviations and Acronyms
AF  atrial fibrillation
CI  confidence interval
ERAF  early recurrence of atrial fibrillation
ERAF1 min  successful shock followed by AF within
1 min
ERAF1 h  successful shock followed by AF within
1 h
ERAF1 day  successful shock followed by AF within
24 h
GEE  generalized estimating equation
Table 1. Patient Characteristics
Patient Characteristics
Total
(n  97)
Gender (n, %)
Male 69 (71%)
Age (yrs)
Mean  SD 63  12
Range 31–83
History
Myocardial infarction 13 (13%)
Hypertension 40 (41%)
Cardiomyopathy 30 (31%)
Aortic valve disease/disorder 17 (18%)
Mitral valve disease/disorder 35 (36%)
Tricuspid valve disease/disorder 8 (8%)
Primary/idiopathic electrical disease 2 (2%)
Chronotropic incompetence 3 (3%)
Congestive heart failure 30 (31%)
Congenital heart disease 1 (1%)
CABG 9 (9%)
Ejection fraction (%)
Mean 52
Range 15–91
Left atrial diameter (mm)
Mean 46
Range 11–60
New York Heart Association functional class
I 56 (58%)
II 28 (29%)
III 13 (13%)
Primary atrial arrhythmia
Fibrillation 74 (76%)
Flutter 3 (3%)
Mixed (fibrillation and flutter) 20 (21%)
Arrhythmia pattern
Paroxysmal 30 (31%)
Persistent 64 (66%)
Unknown 3 (3%)
Anticoagulation medication
Coumadin 71 (73%)
Aspirin 15 (16%)
Data are presented as the number (%) of patients or mean value  SD.
CABG  coronary artery bypass graft surgery.
Table 2. Device Data (n  97)
Detection intervals
Atrial tachycardia: 333  40 ms
AF: 278  19 ms
Atrial DFT at implantation: 6.0  4.1 J
Shock programming
On command only: 44 patients (45%)
Automatic only: 29 patients (30%)
Automatic and on command: 24 patients (25%)
Programmed atrial shock energy: 16.5  8.4 J (range 0.4–27 J)
Shock energy relative to DFT at implantation
2 DFT: 156 shocks (19.2%); 22 patients (23%)
2 DFT: 555 shocks (78%); 44 patients (45%)
Number of shocks required to terminate AF episode: 1.2  0.5
Duration of AF before shock: 531  1,042 min (range 0.12–1,290)
Switchback delay programming
On: 512 episodes (47%)
Off: 578 episodes (53%)
Average interval: 765  95 ms
Average delay: 390  627 ms
Atrial rate stabilization programming
On: 759 episodes (70%)
Off: 331 episodes (30%)
Atrial arrhythmia minimal interval: 584  45 ms
Interval increrment: 101  8 ms
AF  atrial fibrillation; DFT  defibrillation threshold.
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and 3) ERAF1 day successful shock followed by AF within
24 h.
For each treated AF episode, the device stored 5 s of
electrographic recordings and 60 atrial and ventricular
marker channel events preceding the initial therapy, as well
as 60 events preceding AF termination. These data were
reviewed by the investigators, and only appropriately de-
tected episodes were included. The date and time of
detection, type of arrhythmia (e.g., fibrillation or tachycar-
dia), median interatrial electrogram interval, total arrhyth-
mia duration and device-defined outcome of therapy were
also recorded. No information was stored after a failed
shock. Therefore, we were unable to quantify the incidence
of successful shocks followed by new AF recurrence before
device confirmation of shock success (Fig. 1).
Analysis. The present study focuses on events after suc-
cessful shock only. Data are reported as the mean value 
SD, unless otherwise specified. The Wilcoxon signed rank
test was used for paired comparisons. To adjust for multiple
episodes in each patient, the generalized estimating equa-
tion (GEE) statistical method with exchangeable correla-
tion was used (11). The GEE model yielded an estimate of
ERAF incidence, along with 95% confidence intervals
(CIs). The univariate associations between prospectively
identified demographic, clinical and device variables and
ERAF (Table 3) were also evaluated using the GEE model.
A multivariate model was then developed using a backwards
elimination method with significant univariate predictors. A
p value 0.05 was considered significant. All analyses were
performed using SAS version 6.12 (SAS Institute Inc.,
Cary, North Carolina).
RESULTS
Data from 146 patients were compiled. The system could
not be implanted in two patients (inability to implant the
atrial lead in 1; unacceptably high ventricular defibrillation
threshold in 1). At the time of this analysis, the device had
been implanted for 12.7  6.1 months (range 0.1 to 25.9
months). A total of 1,427 shocks were delivered to 1,200
spontaneous atrial episodes in 107 patients. Of these 1,200
episodes, 1,092 were successfully converted in 97 pa-
Figure 1. Real-time telemetered data from implanted device. An atrial cardioversion shock (arrow) is delivered, resulting in termination of atrial fibrillation
(AF). However, AF recurrence is swift, occurring well within the five consecutive ventricular beats required for device determination of success. Had this
been an ambulatory event, the device would have characterized it as a failed shock. As such events were not stored by the device, the incidence of this
phenomenon is unknown. Aegm  atrial electrogram; EKG  surface electrocardiogram; MC  marker channel.
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tients. These 97 patients formed the cohort of the present
study.
Unsuccessful pacing therapies preceded shocks in 726 AF
events (66%) among 82 patients (85%). The median number
of successful cardioversion shocks per patient was six (13
patients with 1 shock, 35 patients with 2 to 5 shocks and 18
patients with 6 to 10 shocks). There were 519 commanded
shocks (47.5%) among 61 patients (63%).
The per-patient incidences of ERAF (patients with one
or more ERAF event[s]) were 44% for ERAF1 min, 61% for
ERAF1 h and 70% for ERAF1 day. The per-episode inci-
dences of ERAF (successful cardioversions events followed
by ERAF) were 17% for ERAF1 min, 30% for ERAF1 h and
43% for ERAF1 day. A disproportionate number of ERAF
events occurred within minutes of cardioversion (Fig. 2).
Individual patient incidences of ERAF were highly variable.
Tables 3 and 4 summarize the results of univariable and
multivariable analyses, respectively, assessing for a relation-
ship between ERAF and clinical and device variables. There
was no significant relationship between ERAF1 min,
ERAF1 h or ERAF1 day and the number of successful
shocks. Factors emerging in the multivariable analysis as
significantly associated with each ERAF classification in-
cluded AF duration3 h before cardioversion, failed shocks
delivered before the successful one and the absence of a
previous myocardial infarction. Of these, AF duration 3 h
before shock was a very powerful factor associated with a
threefold increase in the incidence of ERAF. Analysis of the
median AF duration showed that the incidence of ERAF
decreased as the pre-cardioversion AF duration increased
(Fig. 3).
To exclude a bias due to event clustering, a subset of 79
patients (444 shocks) in whom no AF was observed for at
least 24 h before successful cardioversion was assessed. The
per-patient incidences of ERAF were 31% for ERAF1 min,
45% for ERAF1 h and 56% for ERAF1 day. The per-episode
incidences were 16% for ERAF1 min, 25% for ERAF1 h and
Table 3. Relative Risk of Early Recurrence of Atrial Fibrillation
for Clinical and Device Variables (Univariate Analysis)
ERAF1 min ERAF1 h ERAF1 day
Age 60 yrs 1.17 (0.66) 1.15 (0.63) 0.92 (0.76)
Gender (male) 2.48 (0.03) 1.51 (0.18) 1.54 (0.10)
Paroxysmal AF 2.49 (0.006) 1.65 (0.07) 1.75 (0.03)
Cardiomyopathy 1.37 (0.35) 1.35 (0.24) 1.38 (0.19)
Previous MI 0.27 (0.009) 0.29 (0.01) 0.38 (0.03)
CHF 1.33 (0.43) 1.33 (0.32) 1.41 (0.18)
Hypertension 1.36 (0.36) 0.93 (0.79) 0.78 (0.31)
LVEF 40% 0.58 (0.21) 0.61 (0.13) 0.61 (0.10)
LA size  40 mm 1.92 (0.21) 0.81 (0.61) 0.92 (0.77)
Class I AAD 0.81 (0.76) 0.62 (0.32) 0.92 (0.79)
Class III AAD 1.64 (0.22) 1.22 (0.44) 0.98 (0.92)
Beta-blocker 0.70 (0.40) 0.75 (0.37) 0.79 (0.55)
Implantation within
6 months
1.36 (0.43) 1.39 (0.28) 1.01 (0.96)
Shock 2 DFT 0.90 (0.82) 0.86 (0.67) 1.23 (0.63)
On-command shock 0.51 (0.15) 0.68 (0.22) 0.60 (0.14)
1 Shock required 1.94 (0.002) 1.75 (0.001) 1.40 (0.04)
AF duration 3 h 3.93 (0.001) 3.70 (0.001) 2.64 (0.001)
No shock before 24 h 0.58 (0.09) 0.56 (0.01) 0.59 (0.01)
Shock delivery 8 AM
to 8 PM
0.53 (0.003) 0.68 (0.02) 0.79 (0.18)
No AF before 24 h 1.19 (0.47) 1.28 (0.18) 1.41 (0.07)
Prevention therapies* 1.32 (0.44) 1.14 (0.60) 1.35 (0.15)
*Switchback delay and atrial rate stabilization (see text). Data are presented as the
relative risk, with the univariate p value in parentheses.
AAD  antiarrhythmic drug; AF  atrial fibrillation; CHF  congestive heart
failure; DFT defibrillation threshold; ERAF1 min, ERAF1 h and ERAF1 day early
recurrence of atrial fibrillation within 1 min, 1 h and 1 day, respectively; LA  left
atrial; LVEF  left ventricular ejection fraction; ; MI  myocardial infarction.
Figure 2. Timing of onset of early recurrence of atrial fibrillation (ERAF)
events. (Top) Incidence of ERAF onset over the first hour after successful
shock (355 shocks, 33% of the total for the study cohort). (Bottom)
Incidence of ERAF over the first 24 h after successful shock (498 shocks,
46% of the total).
Table 4. Relative Risk of Early Recurrence of Atrial Fibrillation
for Clinical and Device Variables (Multivariate Analysis)
ERAF1 min ERAF1 h ERAF1 day
AF duration 3 h 3.86 (0.001) 3.54 (0.001) 2.43 (0.001)
No MI 4.55 (0.001) 3.12 (0.015) 2.56 (0.018)
1 Shock required 2.17 (0.001) 1.96 (0.001) 1.47 (0.022)
Shock delivery 8 AM
to 8 PM
0.58 (0.006) NS NS
No shock before 24 h NS 0.62 (0.016) 0.66 (0.018)
Data are presented as the relative risk, with multivariate p value in parentheses.
NS  not significant; other abbreviations as in Table 3.
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36% for ERAF1 day. The ERAF incidence (any definition)
for pre-cardioversion AF duration 3 h was 11% (95% CI
6% to 18%), significantly lower than the 25% incidence for
pre-cardioversion AF duration 3 h (95% CI 17% to 35%;
p  0.001). Some individuals had multiple successful
cardioversions, some of which were followed by ERAF. In
these individuals, a paired analysis of the median AF
duration demonstrated that successful cardioversions suc-
ceeded by ERAF were performed significantly earlier, rel-
ative to atrial arrhythmia onset, than those not succeeded by
ERAF (Fig. 4).
DISCUSSION
Previous studies. Post-shock ERAF can occur after trans-
thoracic and transvenous cardioversion (1–6). Regarding
transthoracic cardioversion, Yu et al. (2), who defined
ERAF as AF recurrence 1 min after conversion, reported
an incidence of 26% among 50 patients. Daoud et al. (3),
who defined ERAF as AF recurrence 5 min after conver-
sion, reported an incidence of 9% among 337 patients.
Regarding transvenous cardioversion, utilizing temporary
defibrillation lead systems and with ERAF defined as AF
Figure 3. Distribution of early recurrence of atrial fibrillation (ERAF)
incidence, expressed as the percentage of all successful shocks for the study
cohort, based on the duration of atrial fibrillation preceding cardioversion.
Data are presented as generalized estimating equation estimates; error bars
indicate 95% confidence intervals. Note variations in scale between the
graphs.
Figure 4. Paired analysis of median duration of atrial fibrilliation (AF)
preceeding cardioversion in individuals experiencing successful cardiover-
sion shocks with and without early recurrence of atrial fibrillation (ERAF).
The box plot shows the 25th and 75th percentiles. The median value is
shown as a line across the box; error bars define the 10th and 90th
percentiles. Note variations in graph scaling.
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recurrence within 5 min of conversion, several studies have
reported per-patient incidences of ERAF ranging from 13%
to 36% (4–7). No clinical or echocardiographic predictors
were reported. More recent reports have also addressed the
phenomenon of ERAF after transvenous shock cardiover-
sion by permanent lead systems. Wellens et al. (8) demon-
strated 27% per-episode and 51% per-patient incidences of
ERAF (defined as AF recurrence within 1 min) among 41
patients implanted with the Metrix system (Model 3000 or
3020, Guidant Inc., St. Paul, Minnesota) who underwent
cardioversion under direct physician observation. Daoud et
al. (9) reported a per-episode incidence of25% in patients
with this system who underwent ambulatory conversion.
However, due to limitations in event logging by this device,
the exact incidence and timing of ERAF events could not be
determined. Neither of these studies reported factors sig-
nificantly associated with ERAF.
Present study. Our data confirm and extend those of the
aforementioned studies. First, we present a broader and
potentially more clinically relevant analysis of ERAF. From
the patient’s perspective, ERAF is not limited to minutes
after cardioversion. For example, the need to deliver addi-
tional cardioversion shocks for new AF events within hours
or days of a previous successful shock might be viewed as
equally objectionable as the need to deliver additional
shocks within minutes. Although a disproportionate num-
ber of ERAF events occurred within minutes of conversion,
a substantial number occurred later. Among recurrent AF
episodes, those that were early versus new (e.g., paroxysms
that would have occurred regardless of how the previous
event was terminated) are difficult to distinguish. However,
we do not believe that new AF episodes significantly
influenced our data, for two reasons: 1) a clinical syndrome
of paroxysmal AF was present in a minority (30%) of the
patients; and 2) in the multivariable analysis of factors
associated with ERAF, clinical AF syndrome was not
important.
Second, we identified associations between several clinical
and device variables and ERAF. Several variables were
independently associated with ERAF. The significant vari-
able that can most easily be influenced by device program-
ming is AF duration. Earlier studies have suggested that a
longer duration of AF is associated with a higher recurrence
rate, linking AF susceptibility to arrhythmia-induced atrial
electrophysiologic substrate remodeling (12–15). In con-
trast, our data demonstrate the opposite. An explanation for
this finding may lie in the duration of AF before cardiover-
sion. In previous studies, the duration of AF was not
controlled but was generally long (days to months). In
contrast, in the present study, AF duration was much
shorter. We speculate that there might have been a period
early after AF onset during which remodeling was insub-
stantial and thus not a factor in determining susceptibility to
AF. During this period, AF duration may have influenced
the activity of sites of origin of AF-triggering atrial prema-
ture depolarizations, with a longer AF duration being more
suppressive (7). Whatever the mechanism, if substantiated,
this finding may alter the way device-based atrial rhythm
control strategies are implemented. For example, shock
therapies may be delayed for hemodynamically stable, tol-
erable AF episodes.
The inverse correlation of a previous myocardial infarc-
tion with ERAF suggests that patients may be stratified for
risk of ERAF based on clinical variables. If substantiated,
such results may assist physicians in choosing an AF
treatment strategy.
The correlation between ERAF and the requirement for
multiple shocks to terminate AF probably reflects AF
recurrence after successful shocks before device confirma-
tion (Fig. 1). This would have been misclassified by the
device as an unsuccessful shock.
Study limitations. We cite the following limitations: 1)
the analysis was based on data acquired retrospectively,
generated in the context of an observational trial uncon-
trolled for multiple factors; 2) because successful termina-
tion of AF by a shock can be preceded by unsuccessful
pacing and shock therapies, it is possible that these therapies
may have influenced ERAF and subacute recurrences; and
3) our data probably underestimate the incidence of ERAF
within the first minute after shock.
The correlations we identified between ERAF and the
analyzed variables require prospective validation.
Conclusions. Early recurrence of atrial fibrillation after
ambulatory shock conversion is common. Factors signifi-
cantly associated with ERAF, as identified in the present
study, may, if subsequently validated, lead to refinement in
patient selection and device programming. With respect to
our speculation about the mechanism of increased ERAF
incidence with decreased pre-shock duration, prospective
confirmation of this concept might foster new AF control
strategies not necessarily limited to those based on implant-
able devices.
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